Source:http://linkedlifedata.com/resource/pubmed/id/15298727
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
8
|
pubmed:dateCreated |
2004-8-9
|
pubmed:abstractText |
Clear cell sarcoma (CCS) is a very rare soft tissue sarcoma with a poor prognosis. It has become apparent through immunohistochemical, ultrastructural, and microarray analyses that CCS is a soft tissue melanocytic neoplasm. Alterations in the p16INK4a/p14ARF gene are common in malignant melanoma, which is the prototypical melanocytic neoplasm. In the present study, we performed a clinicopathologic analysis and investigated p16 and cyclin D1 expression by immunohistochemistry in 14 cases. Furthermore, we investigated genetic changes of various tumor suppressor genes and an oncogene, including p16INK4a/p14ARF, p53, beta-catenin, and APC, in 11 cases. The 5-year overall survival rate in all the patients was 33.3%. A high mitotic rate was a significant adverse prognostic factor (P = 0.004). Decreased expression of p16 was observed in 4 (28.6%) of 14 cases. Overexpression of cyclin D1 was observed in 9 cases (64.3%). SSCP analysis followed by DNA direct sequencing revealed point mutations of the p16INK4a gene in 2 of 11 cases (18.2%). In addition, one case with the p14ARF mutation and 2 cases with the p53 mutation were observed. None of the cases harbored mutation of the beta-catenin or APC gene. Homozygous deletion of the p16INK4a/p14ARF gene was detected in one case. Methylation-specific PCR did not reveal hypermethylation of the p16INK4a/p14ARF promoter region in any of the cases. Three cases harbored genetic alterations of the p16INK4a/p14ARF gene (27.3%). All tumors with genetic alterations of the p16INK4a/p14ARF or p53 gene showed a high mitotic rate or tumor necrosis. These alterations were considered to be influential in the poor prognosis of CCS patients.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Aug
|
pubmed:issn |
1347-9032
|
pubmed:author | |
pubmed:issnType |
Print
|
pubmed:volume |
95
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
651-5
|
pubmed:dateRevised |
2006-11-15
|
pubmed:meshHeading |
pubmed-meshheading:15298727-Adult,
pubmed-meshheading:15298727-Child,
pubmed-meshheading:15298727-Cyclin-Dependent Kinase Inhibitor p16,
pubmed-meshheading:15298727-DNA Mutational Analysis,
pubmed-meshheading:15298727-Female,
pubmed-meshheading:15298727-Follow-Up Studies,
pubmed-meshheading:15298727-Gene Expression Regulation, Neoplastic,
pubmed-meshheading:15298727-Genes, p16,
pubmed-meshheading:15298727-Humans,
pubmed-meshheading:15298727-Immunohistochemistry,
pubmed-meshheading:15298727-Male,
pubmed-meshheading:15298727-Middle Aged,
pubmed-meshheading:15298727-Prognosis,
pubmed-meshheading:15298727-Sarcoma, Clear Cell,
pubmed-meshheading:15298727-Soft Tissue Neoplasms,
pubmed-meshheading:15298727-Survival Analysis,
pubmed-meshheading:15298727-Tumor Suppressor Protein p14ARF
|
pubmed:year |
2004
|
pubmed:articleTitle |
Alterations of the p16INK4a/p14ARF pathway in clear cell sarcoma.
|
pubmed:affiliation |
Department of Anatomic Pathology (Second Department of Pathology), Graduate School of Medical Sciences, Kyushu University, Higashi-ku, Fukuoka 812-8582, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|